Schaltbau: Turnaround Progressing at Top-Three Player in Train Doors

October 13, 2018 in Equities, Europe, European Investing Summit, European Investing Summit 2018, European Investing Summit 2018 Featured, Ideas, Micro Cap, Transcripts

Nils Herzing of Active Ownership Capital presented his in-depth investment thesis on Schaltbau Holding (Germany: SLT) at European Investing Summit 2018.

Thesis Summary:

Schaltbau Holding is a German mid-cap company with a top-three position in the niche market for train doors, high-voltage components, and level crossings. The company is positioned in the attractive and growing railway infrastructure and rolling stock market, which is forecasted to grow at a CAGR of 5+% from 2016-2025.

The rail market is attractive, as Schaltbau delivers mission-critical C-components that have high safety regulations and supply obligations of more than thirty years. Thus, customer purchasing behavior is primarily driven by quality rather than cost.

Additional growth comes from the fact that OEMs want a strong number-three player and are therefore willing to give business to Schaltbau instead of the top two players, Knorr-Bremse and Wabtec, especially as the latter recently acquired the train business of GE.

Furthermore, Schaltbau’s well-known brand makes it an excellent buy-and-build platform, and the ongoing trend to e-mobility and renewable energy drives demand for the highly profitable components business.

Due to strategic missteps as well as weak management and supervisory board, the company lost its way in recent years. In 2017, Active Ownership Capital saw an opportunity to become one of the company’s largest shareholders. It has since strengthened the board and management in order to execute on the strategic plan of refocusing the company on the core business and increasing profitability.

Schaltbau is half-way through its turnaround. The shares offers investor an opportunity to buy into an investment idea with indicative upside of up to 170%, an IRR of ~25% over the next four years.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Nils Herzing has worked as a Manager of a German Family Office and is currently working at Active Ownership Capital. B.A. in Management, Philosophy, Art. MSc in Finance from the EBS Business School and EDHEC Business School. CFA Charterholder as of 2016.

LafargeHolcim: Construction Materials Leader Investing in Growth Capex

October 12, 2018 in Equities, Europe, European Investing Summit, European Investing Summit 2018, European Investing Summit 2018 Featured, Ideas, Large Cap, Transcripts

Samuel Weber, an independent wealth manager based in Zug, Switzerland, presented his in-depth investment thesis on LafargeHolcim (Switzerland: LHN) at European Investing Summit 2018.

Thesis Summary:

LafargeHolcim is the leading global construction materials and solutions company serving masons, builders, architects and engineers around the world. The company produces cement, aggregates and ready-mix concrete, which are used in building projects ranging from affordable, small, local housing to the biggest, most technically and architecturally challenging infrastructures.

Lifelong partnerships and the requirement to adapt products to specific customer needs enable LafargeHolcim to build-up a reputation for reliability and quality.

In 2017, LafargeHolcim generated CHF 26+ billion of revenue and almost CHF 6 billion of recurring EBITDA. The company plans to grow those figures by 3-5% and more than 5% per year, respectively and aims to generate a ratio of FCF to recurring EBITDA of at least 40%. If the company reaches those targets, it will generate recurring EBITDA of CHF 7.6+ billion and recurring FCF of CHF 3+ billion in 2022.

As FCF includes both growth and maintenance capex, it understates the company’s true earnings. The investments needed to maintain the status-quo are shown in the footnotes of the annual report and based on these figures, LafargeHolcim’s true earning power will be around CHF 4 billion in 2022.

Applying a P/E multiple of 15x suggests intrinsic value of CHF 60 billion, or CHF 41 billion discounted back to today with a discount rate of 8%. This looks attractive compared with a market cap of less than CHF 30 billion – even more so when considering the attractive dividend yield of 4% – and should compensate investors for the significant profit share of minority shareholders.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Samuel S. Weber is an independent wealth manager based in Zug, Switzerland. He is a passionate value investor, who is focused on generating long-term, market beating returns by investing in high-quality opportunities in the stock market and providing patient capital to SMEs with the overall aim of fostering productive investments in Switzerland and Europe. To achieve the latter, he founded the SW Kapitalpartner GmbH (www.swkapitalpartner.com). Samuel holds a master’s degree in strategy and international management from the University of St. Gallen.

Sidetrade: Owner-Operated Cloud Software Leader in Niche Industry

October 12, 2018 in Equities, Europe, European Investing Summit, European Investing Summit 2018, Ideas, Information Technology, Micro Cap

Jeremie Couix presented his in-depth investment thesis on Sidetrade (France: ALBFR) at European Investing Summit 2018.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Jeremie Couix is a co-founder of HC Capital Advisors based in Germany. Prior to co-founding HC Capital, he worked at Discover Capital as an investment analyst and later as co-portfolio advisor of the fund Squad Growth. Previously, he worked at FORUM Family Office, a value-oriented investment manager based in Munich. Jeremie graduated from EM Lyon Business School in France with an MSc in Management.

Covestro: High-Value Niche Player Misperceived as Commodity Business

October 12, 2018 in Equities, Europe, European Investing Summit, European Investing Summit 2018, European Investing Summit 2018 Featured, Ideas, Large Cap, Transcripts

Antonio Garufi of Decalia Asset Management presented his in-depth investment thesis on Covestro (Germany: 1COV) at European Investing Summit 2018.

Thesis Summary:

Covestro is a German diversified chemicals company with a market cap of €14 billion. It is a leader in insulating materials for sustainable buildings and high-tech materials, coatings, and adhesives.

It will capitalize on long-term trends, such as innovative mobility, a growing population, urbanization, and climate change. Covestro markets thousands of products worldwide and has an innovative company DNA.

While is perceived as a commodity business, it is actually a leader in several high value-added niche markets.

Covestro shares recently traded at an affordable valuation amid forced selling by Bayer and negative market sentiment, namely 4x EV/EBITDA, 6x P/E, and a 13% FCF yield. The company operates in a concentrated industry with high barriers to entry.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Antonio Garufi is a portfolio manager and equity analyst at Decalia Asset Management, based in Geneva since 2017. Previously, he spent one year at Citigroup and three years at J.P. Morgan in London. He then went on the buyside at Astor Investment in Milan, where he was an analyst and co-manager of a thematic hedge fund. He graduated from Bocconi University in 2005, where he is currently a teaching assistant, has a Phd in Business Administration and attended the Value Investing Program at Columbia Business School. He graduated from the Strategic Financial Analysis program at Harvard Business School in 2018.

Boskalis: Dredging and Maritime Services Provider in Cyclical Recovery

October 12, 2018 in Equities, Europe, European Investing Summit, European Investing Summit 2018, Ideas, Mid Cap

Mallika Paulraj, Value Investor presented her in-depth investment thesis on Boskalis (Netherlands: BOKA) at European Investing Summit 2018.

Thesis Summary:

Boskalis constructs and maintains ports, waterways, coastlines, and riverbanks. The company provides dredging services and also engages in land reclamation activities. Royal Boskalis Westminster offers hydraulic engineering, coastal protection, and land reclamation solutions. The share price is low due to a cyclical dip in the share price.

The company has been overly punished for its falling order book, which is now picking up and in a good place to pick up on a growing need for flood protection worldwide. The market cap is €3.7 billion and has recently seen increased and new investment from highly regarded investors.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Mallika Paulraj’s mission is to help individual investors make sense of the world of investing. She attempts to do this with humour and practicality through her writing and speaking. You can follow her blog Four Minute Investing at www.fourminuteinvesting.com. Her primary interests are investment education as well as searching for equity investments that increase in value with a three- to five-year horizon. Mallika’s secondary interests are how to invest for the long term (asset allocation, pension funds, trusts, family offices and endowments). She has been a guest lecturer at London Business School on value investing. Mallika has a BA from Stanford University, an MSc from the London School of Economics, and she has completed the Investment Management Programme at London Business School.

Yara: Outlook Brightening for World’s Largest Fertilizer Producer

October 12, 2018 in Equities, Europe, European Investing Summit, European Investing Summit 2018, European Investing Summit 2018 Featured, Ideas, Large Cap, Transcripts

Stuart Mitchell of S. W. Mitchell Capital presented his in-depth investment thesis on Yara International (Norway: YAR) at European Investing Summit 2018.

Thesis Summary:

Yara International is the world’s largest fertilizer producer (ammonia, nitrates, and NPKs). The company is also developing a higher value-added crop nutrition business.

Recent history has been challenging for Yara. Following the 2011-2014 farming boom, grain prices fell sharply, stressing the industry. At the same time, Yara and other fertilizer producers had to cope with the extra capacity built up in the “good times”. In particular, western manufacturers faced a flood of cheap urea exports coming out of China.

The outlook, however, is beginning to look more positive again. Chinese exports have fallen by ~60% since the start of 2018. Chinese manufacturers face more stringent environmental rules (75% of production is coal-based) and were heavily loss-making in 2016 ($2 billion). At the same time, Yara’s competitive position has improved relatively due to lower gas feedstock prices.

More difficult market conditions prompted Yara to cut costs aggressively. Management plans to reduce the cost base by $500 million, or ~50% of 2016 EBIT. The team also hopes to add a further $600 million to sales by expanding premium products, most notably in Brazil, and by increasing ammonia production.

Trading at 1.2x book value, the shares appears enticingly valued for a company that has generated 15% ROCE over the cycle in the past.

The following transcript has been edited for space and clarity.

My presentation focuses on Norwegian fertilizer producer Yara, on which we’ve done a great deal of work, and we think there’s a significant upside. Yara is not such a well-known company, so let me start with a brief introduction. This is the leading manufacturer of fertilizers, with an evenly spread global production – the US, North America, Asia, Africa, and Brazil. The current gas price, the glut of capacity, and limited export opportunity in the US place it at some disadvantage to producers who are purely in the US and benefit from the low gas price. If you look at Yara’s productivity charts and compare the quality of its assets, you will see it generally comes out in the very top decile for all its plants compared to other producers worldwide. It is number one in nitrates and NPK. This great specialist business came out of the Norsk Hydro Group, focusing purely on the manufacture of fertilizers. We have a number one player globally, fabulous quality, and the most efficient production capacity. The slight disadvantage of being a global player as opposed to a US-based one is, in our opinion, a shorter-term thing.

Among Yara’s strengths is its fully integrated business model, and there are numerous advantages and efficiencies coming from that. It has also built up a significant industrial business – it has managed to combine the byproducts of producing fertilizer to make extra products for non-fertilizer industrial clients. The top product is AdBlue, which is used to reduce NOx emissions in diesel engines. People sometimes forget there is an advantage to being the largest producer because it means you can source raw material more cheaply than anybody else and can maximize capacity at a particular time in the cycle in a certain region, thus produce more cheaply. At the moment, Yara has been trying to push as much through the US as it can. Yara’s global price is a bit cheaper than the price of gas worldwide – it is a significant advantage to be able to buy gas at $5 compared to $5.5 in Europe. The US gas price is far lower than everywhere else, but that will normalize over time.

Another interesting thing about this company is that it’s got a great record, maybe better than can be expected from a cyclical company. Yara has achieved this because it is more efficient than anybody else at producing fertilizer. It’s a cyclical record, but it’s stronger on a long-term basis. The ROIC generated over time has been surprisingly good for a business like this – we have annual numbers such as 10%, 23%, 29%, and 25%. During the industry downturn in 2016, ROIC fell quite sharply to 8% and then 4%. CROGI (cash return on gross investments) has been 13.5% on average, which is an exceptionally and surprisingly high number for a business like this, but in 2017, we had a trough, with CROGI dropping to 6.5%.

What was our chance to buy this company? This is a cyclical industry, and the share price has been really depressed on the back of a combination of new capacity coming on and unusually weak demand, which normally follows a period of poor harvest and reduced cash flows, so the farmers are less able to spend money on fertilizer. In 2017, there was a significant amount of excess capacity in urea, which is the basic ammonia feedstock for fertilizers. At the same time, it was a period of unusually weak demand, so we hit a perfect storm. Urea prices came down to $200 a tonne compared to $600 a tonne at the peak. We’ve seen a sharp fall in prices during this period of excess capacity and weakish demand. It’s quite interesting if you consider things like new build parity. If you were to build new capacity today, you’d have to do urea price at $320 a tonne just to cover your cost of capital. Any new capacity is a highly complex process – it can take four to five years to build a new plant. The amount of new capacity coming on should be significantly below demand, and then we’d also expect demand to be a bit higher as it balances out from the weaker periods we’ve had over the past few years.

At this time of excess capacity and challenged demand, Yara’s profits have come under a lot of pressure. Sales fell from NOK 111 billion in 2013 to NOK 94 billion in 2017, and EBIT and net income more than halved. In 2017, we even had cash outflows, and ROIC dropped to 4%. This created the wonderful opportunity to buy this nice company which generates, over the cycle, impressive returns on capital because of the various advantages it has, such as technological superiority, spread, size, and the resulting ability to purchase products more cheaply than anybody else. It has also worked hard to develop interesting mixes of trace products and more complex fertilizers than the competition.

Urea demand remains far below trend while supply growth slows. Back in the glory days of 2006, utilization rates were near 92%, and that’s when urea prices were right up in the $600 levels. In 2016, at the bottom of the cycle, utilization was 79%. We expect the rate to pick up sharply over the next few years.

Another interesting piece of work we did was look at the age of ammonia capacity. A lot of it is extremely old now and very unprofitable. Yara is one of those groups that have constantly innovated and upgraded capacity so that in everything it does, it is in the top decile of its productivity curve. There’s a lot of highly inefficient capacity, and with prices as low as they are now, this capacity will either be closed down or replaced. If it’s replaced, urea prices have to be much higher to cover the cost of that capital investment.

The first thing Yara did was to try and cut costs, as any good company would do. You have to assume the fertilizer price isn’t going to increase although we think there’s a good chance it will do. Then you try and bring your profit back up just by cutting cost. Yara put in place an aggressive profit improvement program, the idea being to increase EBITDA by $500 million per annum by 2020. The company is already quite far ahead of this. The program aims for 10% greater production efficiency, 25% lower fixed costs, and 35% lower variable costs. Slightly more controversial is 35% from higher volumes, but the company is also adding capacity as this whole process goes through.

With the extra capacity added in the past few years, assuming urea and fertilizer prices stay where they are today, it should add $1.1 billion to 2020 profits. That’s almost the same level as the profit Yara made back in 2017 of $1.4 billion. Our guess is that without cyclical upturn, the shares would be trading at 5x EBITDA, which is quite an attractive valuation with no increase in urea price, just work it is doing on the cost side. It’s interesting that the shares are still trading at a big discount to competitors. When I say competitors, it’s mostly those producing fertilizers in the US. They have the advantage provided by the glut of natural gas, but this should even out over the cycle, as it normally does. You get new capacity coming on Europe. At the same time, we’re going to get the ports and the ships so that glut of capacity can be exported out to the US, and this competitive advantage will even out over the next few years, in our opinion.

What makes things all the more interesting is that we believe Yara can go a lot further. It’s a very traditional European company, extremely asset-rich and conservatively run. It has got a number of gems that are difficult for the market to appreciate, and Yara can do a number of things which would surprise existing shareholders and could help drive the share price up quite significantly. The first thing is the industrials business, the one that uses the byproducts of fertilizer production to make various industrial products. In talks with people from the industry, we have found that these will be highly attractive, specialty chemicals to some chemical groups. Looking at the kind of prices these assets fetch in M&A, we think the business could be worth 25% of the current market cap. Yet, at the moment, it only makes 12% of group EBITDA. We believe it’s something which could surprise a number of investors. If it were to announce the sale of this business somewhere around this price, it could drive the share price significantly higher. However, it’s also complicated because these are products manufactured in existing Yara complexes so there would have to be some supply agreement. Despite the complexity, this is normal within the industry, and some other companies have done it.

We’ve also studied extensively the improvement program and believe the company can go quite a lot further than it has said. It’s an aggressive program, but looking at the costs similar companies have been able to take out in difficult times and how much Yara has exceeded the program so far, we think it could save up a further $500 million. Our hope is that it will come up with a raised guidance for the savings from the improvement program. The management has already indicated it can do $700 million to $800 million, but our view is it could go way higher.

The other thing which intrigued us is that Yara has a lot of really interesting assets sitting on its balance sheet at pretty much nothing, but we consider them quite valuable. It has got ports and terminals, for example, and those could be worth far more than the balance sheet suggests. There could be a possibility for sale and leaseback. We could be talking of value of $1.5 billion or $2 billion. That’s something which could really surprise investors and help push the share price further.

Pulling all this together, we talked about the current level of EBITDA, we looked at the extra capacity and the improvement program and what that could bring in the EBITDA, and we looked at the extra cost-cutting. But then we considered the impact of urea prices back at $430, which is a recent peak and would justify new build of capacity, and we find the shares would be trading at something like 3.5x earnings. That looks difficult to achieve right now because we’re at the bottom of the cycle and the cost-cutting program has to proceed, but our guess is the business of a company with proven quality can generate such returns over the long term. I think we have a tailwind now. With very little new capacity coming on in the fertilizer area and demand recovering nicely, there’s a good chance we’ll start to see the value of these assets and then sharply higher profits over the next few years. It seems to have a PER of 3.6x for what probably would be a midcycle urea price that is too cheap, and why not pay 7x, 8x, or 9x for an asset of this quality?

To sum up, Yara is a really good business that has had super quality over the cycle and generated great returns. We were presented with a good opportunity when it faced a perfect storm with all the new capacity coming on and unusually weak demand. The company put in place an aggressive restructuring program, but we think it can go a lot further. There are various hidden valuable assets which the market isn’t fully aware of, and if they’re externalized, it should drive the share price significantly further.

The following are excerpts of the Q&A session:

Q: Stuart, thank you so much for articulating your thesis here for our benefit. Could you comment a bit more on capital allocation and whether there’s anything you might prioritize differently than the management is doing at this time?

A: One of the big challenges of capital allocation in a firm like this is that it takes an awfully long time to build a plant, not only planning but also the context. The region of the world where you’re operating can change dramatically during the time you’re building the plant. One of the obvious questions is why not build more plants in the US, where you have the benefit of lower gas prices. The trouble with that is there are ports and terminals being built to start exporting this glut of excess gas. I’m not totally clear on whether it makes sense to add more capacity in America at this stage of the cycle. There could be a case for it.

The other part is value-added products, and Yara is in the process of doing this. One area in which it is a global leader is digital farming. It’s all about farmers being able to look at a field and see where they’re wasting fertilizer. There are some parts of the field which need more fertilizer than others, and Yara sells this as a package to its farmers. It offers them value-added products, a tailored package of a mix of different fertilizer products that exactly fit the farmers’ land. We think that’s something it should continue to allocate more capital to.

Looking at the bigger question of asset management, selling the industrial business would make a lot of sense; Yara could either pay that cash out to investors or reinvest it back in productivity and make the core business even stronger. It could also reconsider owing its terminals. These assets are quite valuable to other groups, which can perhaps optimize and run them better as part of a portfolio of terminals across the world. I think there’s a reasonable case for that as well. Overall, this is a very well-managed company, with a CEO and CFO among the most impressive ones I’ve met. Still, some of us think they could maybe go a bit further.

Q: What companies would you consider the closest comparables here?

A: It’s really difficult to compare. The best are the Americans, the ones generating the highest returns, and then you have a number of groups operating within larger chemical businesses out of the Middle East. But there’s nothing quite like Yara, which is a global player purely focused on fertilizer production. The others tend to be within larger industrial groups.

Q: What data points could someone track to either validate or challenge your thesis over time?

A: One thing you’ve got to keep on top of is the fertilizer price. It is just beginning to rise nicely now, and if we’re right about the tightening up of the market, it should move quite higher. Since natural gas is the feedstock, the second thing you’ve got to watch closely is the gas price in Europe. You need to keep a close eye on the competitive advantage American producers currently have and hope that the gap starts to narrow as more capacity comes onstream in Europe, port facilities are built in the US, and the products start to get exported. That’s a critical factor because it could be the extra trigger for this company to trade more in line with the American rivals that have this cheap feedstock.

From a super long-term value perspective, you’ve got to make sure you get all the latest analyses that look at the productivity of ammonia and fertilizer plants across the world. Its plants need to be in the top quartile ranking. This is taking out the effect of different gas prices in different parts of the world, looking at straight productivity, the amount of yield coming out of a plant, and the number of workers. For the long-term value case, the company has to stay in the top decile across its plants.

About the instructor:

Stuart Mitchell is the Managing Partner and CIO of S. W. Mitchell Capital and the Investment Manager of two funds; the S. W. Mitchell European Fund and the SWMC European Fund, as well as a number of managed accounts. Prior to founding SWMC in 2005 Stuart was a Principal, Director and Head of Specialist Equities at JO Hambro Investment Management (JOHIM, now Waverton Investment Management). At JOHIM he set up and managed the Charlemagne Fund, a long/short European fund, and the JOHIM European Fund, a long only European fund. The JOHIM European Fund rose by 133% since inception in December 1998 until March 2005 compared with 8% for the benchmark index and was number 1 rated by Micropal within its sector and three star ranked by S&P. Upon leaving university in 1987 Stuart joined Morgan Grenfell Asset Management (MGAM) and soon afterwards assumed responsibility for managing the continental European equity assets for MGAM’s British pension fund clients. Stuart was appointed a director of MGAM in 1996. He was then made Head of European Equities and was responsible for $27 billion of equity assets. Whilst at MGAM he managed the Morgan Grenfell European Fund which rose by 123% from January 1990 to June 1996 compared with 85% for the benchmark index and was awarded 1st place by Micropal (5 year awards) in 1996. Stuart was born in Scotland and educated at Fettes College and St. Andrews University where he read Medieval History. He is also a graduate of the Owner/President Management programme from the Harvard Business School. Stuart speaks English and French.

BBA Aviation: Competitively Strong Provider of Aviation Services for Private Jets

October 12, 2018 in Equities, Europe, European Investing Summit, European Investing Summit 2018, Ideas, Mid Cap

Markus Matuszek of M17 Capital Management presented his in-depth investment thesis on BBA Aviation (UK: BBA) at European Investing Summit 2018.

Thesis Summary:

BBA Aviation is one of the largest providers of business and general aviation services, focusing on private jets. BBA also provides engine and repair services and support for legacy aircraft systems, which require specialist knowhow and certification.

The company has become a top-three global player due to several acquisitions. BBA’s ground services enjoy a quasi-monopolistic position, allowing management to steadily increase pricing.

The US market, representing 80+% in global private jet traffic, is still recovering toward its pre-financial crisis peak, while benefiting from trends such as making private jet travel more accessible through cheaper planes, jet sharing programs, or even “uberization” effects.

BBA is growing organic revenue by 2-3% annually in real terms. Operating leverage of ~1.5x allows for over-proportional EPS growth and continued ROIC of 10+%. Further operational improvements will allow a reduction of net debt to ~$800 million.

The shares trade at a discount to their historic range of multiples, with recent trading multiples at 10x EV/EBITDA, 8.3x cash flow, and a dividend yield of 4.1% (all based on 2020 estimates). Using conservative valuation assumptions, BBA may be worth GBP 4.50 per share, providing ~50% upside from recent levels.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Markus Matuszek is an investor and entrepreneur. He is the founder and Chief Investment Officer of M17 Capital Management, a to be launched value equity long/short fund, biased towards European ideas (listed securities only). Prior to that he ran asset management and advisory firm Hermes Capital Management, advising entrepreneurs, HNWI and funds on strategic, financial and operational matters as well as investing some of their assets in liquid and illiquid strategies. He has been investing in listed securities, private companies and real estate over 13 years with a solid track record. A firm believer in value investing principles, Markus does apply them across the entire capital structure and asset classes. Earlier in his career, Markus was a as senior advisor / interim manager with extensive advisory and hands-on work in strategy, restructuring, organizational change, corporate finance and risk management, M&A advisory, private equity, real estate and investment management in Western Europe, Eastern Europe and the US. His education includes a M.A. in finance, accounting and controlling from the University of St. Gallen (Switzerland), a master degree from CEMS and dual MBAs from Columbia Business School and London Business School. Furthermore, he studied at the Warsaw School of Economics and University of Geneva and received several merit-based fellows and scholarships. He is also a CFA charterholder.

Dermapharm: Growing, Family-Owned Non-Prescription Pharma Company

October 12, 2018 in Equities, Europe, European Investing Summit, European Investing Summit 2018, Health Care, Ideas, Small Cap

Sebastien Lemonnier of INOCAP Gestion presented his in-depth investment thesis on Dermapharm (Germany: DMP) at European Investing Summit 2018.

Thesis Summary:

Dermapharm is a family-owned leading specialty pharma player in Germany. It focuses on branded products, offering a mix of originator and patent-free medicals in growing niche markets with low competition and high margins. Run by a strong management team for the past two decades, the high-single-digit expansion strategy is driven by a rich in-house development pipeline of new products, along with a proven “buy and build” track record and international expansion of its OTC hyperthermia medical device business. Combined with operational excellence and margin improvement, top-line growth should result in disproportionate operating profit growth, improving EBIT margin to more than 20%. Publicly traded since February 2018, Dermapharm remains a neglected stock while providing high-quality fundamentals, including strong results in the past two quarters. Management recently confirmed guidance for top-line growth of 20-25+% and EBITDA of 22-27+%. The shares recently traded at ~13x 2019E EBIT.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Sebastien Lemonnier started his carreer in 2003 as financial analyst at Tocqueville Finance. He was promoted as european fund manager in 2006 running the UCIT fund Tocqueville Value Europe and pursued his carreer for Mansartis, a Paris based multi family-office in 2012. He joined INOCAP Gestion in 2017, managing Quadrige Europe Midcaps. Sebastien holds a Masters Degree in Financial Management from Panthéon-Sorbonne Paris. As a hobby, he played tennis in competition, but now enjoys playing rugby and english boxing.

Offshore Industry and Borr Drilling: Poised for Cyclical Revaluation

October 12, 2018 in Energy, Equities, Europe, European Investing Summit, European Investing Summit 2018, European Investing Summit 2018 Featured, Ideas, Mid Cap, Transcripts

Simon Caufield of SIM Limited presented his in-depth investment thesis on Borr Drilling (Norway: BDRILL) at European Investing Summit 2018.

Thesis Summary:

Borr Drilling was formed two years ago by former Seadrill executives to take advantage of the depressed market environment. The company purchased modern jack-up rigs (early-cycle play) at depressed prices. Schlumberger owns 14% of Borr, while management owns another 14%. The oil industry E&P spending downturn since 2014 has been the worst in more than 35 years, driving down offshore drilling activity, rig utilization, and day rates. Driller stock prices are up to 90% below their 2007-2008 peaks, driven by the effects of operating and financial leverage on earnings and Mr. Market’s manic depressive attitude to the prospects for recovery. There are numerous early signs that the cycle might be turning, including contract tendering and industry sentiment. Recent valuations and prior cycles suggest potential trough-to-peak gains of 6x. Tor Olav Troim, Borr’s Chairman, helped billionaire John Fredriksen set up Seadrill in 2005 and make it the world’s biggest offshore driller in less than a decade before the two men fell out in 2014. He never thought he would get into offshore rigs again, but the opportunity proved “irresistible” when the market crashed with oil’s collapse and he was offered two initial rigs for a quarter of their construction price.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Simon Caufield is Managing Director at SIM Limited, a UK-based investment firm. Simon founded the firm in 2007 after selling his stake in Nomis Solutions, a B2B enterprise software company he founded in 2002. Previously, Simon was a management consultant for more than a decade, including at Mercer Management Consulting. He also writes the “True Value” investment newsletter for MoneyWeek, a UK financial magazine. Simon has an MA in Engineering from Cambridge University.

MOI Global